Relapse of lepromatous leprosy after WHO/MDT with rapid bacterial growth

Leprosy Review

Volumn 73, Issue 4, 2002, Pages 386-388

  Oliveira, M L W ^a   Pierro, A P S M ^a   Silveira, P A M ^a   Campos, M M C ^a   Vilela, M F ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CLOFAZIMINE; DAPSONE; LEPROSTATIC AGENT; PREDNISOLONE; RIFAMPICIN;

AGED; ARTICLE; BACTERIAL GROWTH; CASE REPORT; ECZEMA; HISTOPATHOLOGY; HUMAN; LEPROMATOUS LEPROSY; MALE; MYCOSIS FUNGOIDES; NEURITIS; PATIENT EDUCATION; PERSISTENT INFECTION; RASH; RELAPSE; WORLD HEALTH ORGANIZATION;

EID: 0036952451     PISSN: 03057518     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (10)

1. Waters MFR. Relapse following various types of multidrug therapy in multibacillary leprosy. Lepr Rev, 1995; 66: 1-9.
2. WHO. The Leprosy Unit Division of control of Tropical Diseases. Risk of relapse in leprosy. WHO/CTD/LEP/ 1994, 94.1.
3. Girdhar BK, Girdhar A, Kumar A. Relapses in multibacillary leprosy patients: effect of length of therapy. Lepr Rev; 2000; 71: 144-153.
4. Shaw IN, Natrajan MM, Rao GS et al. Long-term follow up of multibacillary leprosy patients with high BI treated with WHO/MDT regimen for a fixed duration of two years. Int J Lepr, 2000; 68: 405-409.
5. Waters MFR, Rees RJW, McDougall AC, Weddell AGM. Ten years of dapsone in leprosy: a clinical, bacteriological and histological assessment and the finding of viable leprosy bacilli. Lepr Rev, 1974; 45: 288-298.
6. Subcommittee on Clinical Trials of the Chemotherapy of Leprosy (THELEP) Scientific Working Group of the UNDP/World Bank/WHO Special Programme for Research and Training in Tropical Diseases. Persisting Mycobacterium leprae among THELEP trial patients in Bamako and Chingleput. Lepr Rev, 1987; 58: 325-337.
7. Oliveira, MLW. A Cura da Hanseníase. An bras Dermatol, 1997; 72: 63-69.
8. Opromolla, DVA. Terapêutica da Hanseníase. Medicina, Ribeirão Preto, 1997; 30: 345-350.
9. Pattyn SR, Groenen G, Bourland J. The incubation time of relapses after treatment of multibacillary leprosy with rifampicin containing regimens. Eur J Epidemiol, 1988; 4: 231-234.
10. Ji B. Does there exist a subgroup of MB patients at greater risk of relapse after MDT? Lepr Rev, 2001; 72: 3-7.